8 Interferon-α: results from randomized trials

Alimena, 1988, Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration, Blood, 72, 642, 10.1182/blood.V72.2.642.642 Allan, 1995, UK Medical Research Council randomised, multicentre trial of interferon-αn 1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response, Lancet, 345, 1392, 10.1016/S0140-6736(95)92596-1 1988, Secondary prevention of vascular disease by prolonged antiplatelet treatment, British Medical Journal, 296, 320, 10.1136/bmj.296.6618.320 1996, Low dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia, Bone Marrow Transplant, 17, S19 Broustet, 1991, Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukemia: preliminary results of an open French multicentric randomized study, European Journal of Cancer, 27, S18, 10.1016/0277-5379(91)90558-U 1997, Interferon versus chemotherapy for chronic myeloid leukaemia: an overview of the randomised trials, Journal of the National Cancer Institute Counsell, 1994, The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis?, British Medical Journal, 309, 1677, 10.1136/bmj.309.6970.1677 Dickersin, 1993, NIH clinical trials and publication bias, Online Journal of Current Clinical Trials Dickersin, 1992, Factors influencing publication of research results, Journal of the American Medical Association, 267, 374, 10.1001/jama.1992.03480030052036 1992, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women, Lancet, 339, 1 Easterbrook, 1991, Publication bias in clinical trials, Lancet, 337, 865, 10.1016/0140-6736(91)90201-Y Guilhot, 1997, Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia, New England Journal of Medicine, 337, 223, 10.1056/NEJM199707243370402 Hehlmann, 1994, Randomized comparison of interferon-alpha with busulphan and hydroxyurea in chronic myelogenous leukemia, Blood, 84, 4064, 10.1182/blood.V84.12.4064.bloodjournal84124064 1994, Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia, New England Journal of Medicine, 330, 820, 10.1056/NEJM199403243301204 Jacobson, 1991, Reduced toxicities using interferon-alpha (IFN) and hydroxyurea in chronic myelogenous leukemia (CML), 6, 254 Machin, 1987, Statistical Tables for the Design of Clinical Trials, 94 Moro, 1991, The treatment of chronic myelogenous leukemia with interferon alfa-2b plus hydroxyurea versus hydroxyurea alone, Haematologica, 76, 117 Morra, 1992, The role of interferon in the treatment of chronic myelogenous leukemia: results and prospects, Leukemia and Lymphoma, 6, 305, 10.3109/10428199209053562 Niederle, 1991, Interferon alpha-2b in acute and chronic phase chronic myelogenous leukaemia: initial response and long-term results in 54 patients, Eur J Cancer, 27, 7, 10.1016/0277-5379(91)90556-S Ohnishi, 1995, A randomized trial comparing interferon-alpha with busulphan for newly diagnosed chronic myelogenous leukemia in chronic phase, Blood, 86, 906, 10.1182/blood.V86.3.906.906 Shepherd, 1991, Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension: results of MRC CML II trial comparing busulphan with busulphan and thioguanine, British Journal of Haematology, 79, 185, 10.1111/j.1365-2141.1991.tb04520.x Talpaz, 1983, Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia, Blood, 62, 689, 10.1182/blood.V62.3.689.689 Talpaz, 1986, Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia, New England Journal of Medicine, 314, 1065, 10.1056/NEJM198604243141701 Talpaz, 1987, Clinical investigation of human alpha interferon in chronic myeloid leukemia, Blood, 69, 1280, 10.1182/blood.V69.5.1280.1280